home *** CD-ROM | disk | FTP | other *** search
- Federal Register
- Vol. 59, No. 126
- Friday, July 1, 1994
-
- 21 CFR Part 520
-
- Oral Dosage Form New Animal Drugs; Praziquantel, Pyrantel Pamoate, and
- Febantel Tablets
-
- AGENCY: Food and Drug Administration, HHS.
-
- ACTION: Final rule.
-
- SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug
- regulations to reflect approval of a new animal drug application (NADA) filed
- by Miles, Inc. The NADA provides for the oral use in dogs of either of two
- tablets containing different concentrations of praziquantel, pyrantel pamoate,
- and febantel for the removal of tapeworms, hookworms, ascarids, and whipworms.
-
- EFFECTIVE DATE: July 1, 1994.
-
- FOR FURTHER INFORMATION CONTACT: Marcia K. Larkins, Center for Veterinary
- Medicine (HFV─112), Food and Drug Administration, 7500 Standish Pl.,
- Rockville, MD 20855, 301─594─0614.
-
- SUPPLEMENTARY INFORMATION: Miles, Inc., Agriculture Division, Animal Health
- Products, P.O. Box 390, Shawnee Mission, KS 66201, filed NADA 141─007 that
- provides for the oral use in small dogs (up to 11.4 kilograms (kg) or 25
- pounds (lb) of a tablet containing 22.7 milligrams (mg) of praziquantel, 22.7
- mg of pyrantel (as pyrantel pamoate), and 113.4 mg of febantel for the removal
- of certain tapeworms, hookworms, ascarids, and whipworms. The NADA also
- provides for the use in medium and large dogs (11.8 kg and or over 26 lb and
- over) of a tablet containing three times the preceding concentrations. The
- NADA is approved as of May 19, 1994, and the regulations are amended in part
- 520 (21 CFR part 520) by adding new 520.1872 to reflect the approval. The
- basis for approval is discussed in the freedom of information summary.
-
- Under section 512(c)(2)(F)(ii) of the Federal Food, Drug, and Cosmetic Act (21
- U.S.C. 360b(c)(2)(F)(ii)), this approval for nonfood producing animals
- qualifies for 3 years of marketing exclusivity beginning May 19, 1994, because
- the application contains reports of new clinical or field investigations
- (other than bioequivalence studies) essential to the approval of the
- application and conducted or sponsored by the applicant.
-
- In accordance with the freedom of information provisions of part 20 (21 CFR
- part 20) and 514.11(e)(2)(ii) (21 CFR 514.11(e)(2)(ii)), a summary of safety
- and effectiveness data and information submitted to support approval of this
- application may be seen in the Dockets Management Branch (HFA─305), Food And
- Drug Administration, rm. 1─23, 12420 Parklawn Dr., Rockville, MD 20857,
- between 9 a.m. and 4 p.m., Monday through Friday.
-
- The agency has carefully considered the potential environmental effects of
- this action. FDA has concluded that the action will not have a significant
- impact on the human environment, and that an environmental impact statement is
- not required. The agency's finding of no significant impact and the evidence
- supporting that finding, contained in an environmental assessment, may be seen
- in the Dockets Management Branch (address above) between 9 a.m. and 4 p.m.
- Monday through Friday.
-
- List of Subjects in 21 CFR Part 520
-
- Animal drugs.
-
- Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority
- delegated to the Commissioner of Food and Drugs and redelegated to the Center
- for Veterinary Medicine, 21 CFR part 520 is amended as follows:
-
- PART 520 ORAL DOSAGE FORM NEW ANIMAL DRUGS
-
- 1. The authority citation for 21 CFR part 520 continues to read as follows:
-
- Authority: Sec. 512 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
- 360b).
-
- 2. New 520.1872 is added to read as follows:
-
- 520.1872 Praziquantel, pyrantel pamoate, and febantel tablets.
-
- (a) Specifications. Each tablet contains either:
-
- (1) Tablet No. 1: 22.7 milligrams praziquantel, 22.7 milligrams pyrantel base,
- and 113.4 milligrams febantel; or
-
- (2) Tablet No. 2: 68 milligrams praziquantel, 68 milligrams pyrantel base, and
- 340.2 milligrams febantel.
-
- (b) Sponsor. See 000859 in 510.600(c) of this chapter.
-
- (c) Conditions of use (1) Dogs (i) Amount. Administer as a single dose
- directly by mouth or in a small amount of food as follows:
-
- c4,L2,nj,s30,r30,10,10 [col head 1] Weight of animal [col head 2] Kilograms
- [col head 2] Pounds [col head 1] Number of tablets per dose [col head 2]
- Tablet no. 1 [col head 2] Tablet no. 2
-
- 0.9 to 1.8 2 to 4 1/2
-
- 2.3 to 3.2 5 to 7 1
-
- 3.6 to 5.4 8 to 12 1 1/2
-
- 5.9 to 8.2 13 to 18 2
-
- 8.6 to 11.4 19 to 25 2 1/2
-
- 11.8 to 13.6 26 to 30 1
-
- 14.1 to 20.0 31 to 44 1 1/2
-
- 20.4 to 27.2 45 to 60 2
-
- 27.7 to 33.6 61 to 74 2 1/2
-
- 34.0 to 40.9 75 to 90 3
-
- 41.3 to 47.2 91 to 104 3 1/2
-
- 47.7 to 54.5 105 to 120 4
-
- (ii) Indications for use. For the removal of tapeworms (Dipylidium caninum,
- Taenia pisiformis, Echinococcus granulosus); hookworms (Ancylostoma caninum,
- Uncinaria stenocephala); ascarids (Toxocara canis, Toxascaris leonina); and
- whipworms (Trichuris vulpis) in dogs.
-
- (iii) Limitations. Do not use in pregnant animals. Do not use in dogs
- weighing less than 0.9 kilogram (2 pounds) or puppies less than 3 weeks of
- age. Federal law restricts this drug to use by or on the order of a licensed
- veterinarian.
-
- Dated: June 21, 1994.
-
- Stephen F. Sundlof,
-
- Director, Center for Veterinary Medicine.
-
- [FR Doc. 94─16090 Filed 6─30─94; 8:45 am]
-
- BILLING CODE 4160─01─F
-
-
-